Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:associated_with |
gptkb:cancer_treatment
gptkb:Oncology personalized medicine precision oncology targeted therapy biomarker testing molecular targeted therapy ALK inhibitors ALK rearrangements |
| gptkbp:category |
Category D
not recommended |
| gptkbp:chemical_formula |
C22 H24 Cl N5 O2 S
|
| gptkbp:clinical_trial |
Phase II
Phase III |
| gptkbp:developed_by |
gptkb:Roche
|
| gptkbp:discovery_year |
gptkb:2010
|
| gptkbp:dosage_form |
gptkb:capsule
600 mg orally twice daily |
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:formulation |
oral capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alectinib
|
| gptkbp:invention |
patented
|
| gptkbp:marketed_as |
gptkb:European_Union
gptkb:Japan gptkb:United_States gptkb:Alecensa |
| gptkbp:mechanism_of_action |
ALK inhibitor
|
| gptkbp:project |
clinical trials
|
| gptkbp:research_areas |
oncology
pharmacology clinical research |
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
hepatotoxicity
interstitial lung disease bradycardia hypersensitivity reactions QT prolongation embryo-fetal toxicity |
| gptkbp:side_effect |
dizziness
fatigue headache muscle pain nausea diarrhea rash constipation elevated liver enzymes peripheral edema |
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
ALK (anaplastic lymphoma kinase)
|
| gptkbp:used_for |
treatment of ALK-positive non-small cell lung cancer
|
| gptkbp:weight |
393.97 g/mol
|
| gptkbp:bfsParent |
gptkb:EMD_Serono
gptkb:Retevmo |
| gptkbp:bfsLayer |
5
|